Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection

Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image‐defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. Material and Methods From 2009–2012, 39...

Full description

Saved in:
Bibliographic Details
Published inPediatric blood & cancer Vol. 62; no. 9; pp. 1543 - 1549
Main Authors Irtan, Sabine, Brisse, Hervé J, Minard-Colin, Véronique, Schleiermacher, Gudrun, Galmiche-Rolland, Louise, Le Cossec, Chloé, Elie, Caroline, Canale, Sandra, Michon, Jean, Valteau-Couanet, Dominique, Sarnacki, Sabine
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.09.2015
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN1545-5009
1545-5017
DOI10.1002/pbc.25511

Cover

Abstract Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image‐defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. Material and Methods From 2009–2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI. Results Median age at diagnosis was 30 months [range 2–191]. The tumor locations were adrenal (n = 20), paravertebral (n = 13) and perivascular (n = 6). INRGSS stages were L2 (n = 13), M (n = 25) and Ms (n = 1). Eleven tumors (28%) were MYCN‐amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P < 0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P = 0.002), independent of the primary tumor location (P = 0.73), although the number was higher in patients with left versus right adrenal locations (P = 0.004). Patients with neuroblastoma on post‐surgical histology lost more IDRFs (median: 1[0–9]) than patients with ganglioneuroblastoma (median: 0[0–4]) (P < 0.001). The completeness of resection was related only to the number of preoperative IDRFs (P = 0.028). Conclusion IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival. Pediatr Blood Cancer 2015;62:1543–1549. © 2015 Wiley Periodicals, Inc.
AbstractList Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image‐defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. Material and Methods From 2009–2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI. Results Median age at diagnosis was 30 months [range 2–191]. The tumor locations were adrenal (n = 20), paravertebral (n = 13) and perivascular (n = 6). INRGSS stages were L2 (n = 13), M (n = 25) and Ms (n = 1). Eleven tumors (28%) were MYCN‐amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P < 0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P = 0.002), independent of the primary tumor location (P = 0.73), although the number was higher in patients with left versus right adrenal locations (P = 0.004). Patients with neuroblastoma on post‐surgical histology lost more IDRFs (median: 1[0–9]) than patients with ganglioneuroblastoma (median: 0[0–4]) (P < 0.001). The completeness of resection was related only to the number of preoperative IDRFs (P = 0.028). Conclusion IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival. Pediatr Blood Cancer 2015;62:1543–1549. © 2015 Wiley Periodicals, Inc.
Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. From 2009-2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI. Median age at diagnosis was 30 months [range 2-191]. The tumor locations were adrenal (n = 20), paravertebral (n = 13) and perivascular (n = 6). INRGSS stages were L2 (n = 13), M (n = 25) and Ms (n = 1). Eleven tumors (28%) were MYCN-amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P < 0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P = 0.002), independent of the primary tumor location (P = 0.73), although the number was higher in patients with left versus right adrenal locations (P = 0.004). Patients with neuroblastoma on post-surgical histology lost more IDRFs (median: 1[0-9]) than patients with ganglioneuroblastoma (median: 0[0-4]) (P < 0.001). The completeness of resection was related only to the number of preoperative IDRFs (P = 0.028). IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival.
Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. Material and Methods From 2009-2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI. Results Median age at diagnosis was 30 months [range 2-191]. The tumor locations were adrenal (n=20), paravertebral (n=13) and perivascular (n=6). INRGSS stages were L2 (n=13), M (n=25) and Ms (n=1). Eleven tumors (28%) were MYCN-amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P<0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P=0.002), independent of the primary tumor location (P=0.73), although the number was higher in patients with left versus right adrenal locations (P=0.004). Patients with neuroblastoma on post-surgical histology lost more IDRFs (median: 1[0-9]) than patients with ganglioneuroblastoma (median: 0[0-4]) (P<0.001). The completeness of resection was related only to the number of preoperative IDRFs (P=0.028). Conclusion IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival. Pediatr Blood Cancer 2015; 62:1543-1549.
Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined the added value of IDRF assessment after neoadjuvant chemotherapy for predicting surgical resection. Material and Methods From 2009-2012, 39 out of 91 patients operated on in our institution for neuroblastic tumors received neoadjuvant chemotherapy based on ongoing SIOPEN protocols or treatment guidelines. IDRFs were assessed both at diagnosis and preoperatively on CT and/or MRI. Results Median age at diagnosis was 30 months [range 2-191]. The tumor locations were adrenal (n=20), paravertebral (n=13) and perivascular (n=6). INRGSS stages were L2 (n=13), M (n=25) and Ms (n=1). Eleven tumors (28%) were MYCN-amplified. Chemotherapy reduced the number of IDRFs in 54% of patients overall (21/39): 61.5% (16/26) of M and Ms patients, and 38.5% (5/13) of non metastatic patients (P<0.001). The number of IDRFs lost after chemotherapy was proportional to the degree of tumor shrinkage (P=0.002), independent of the primary tumor location (P=0.73), although the number was higher in patients with left versus right adrenal locations (P=0.004). Patients with neuroblastoma on post-surgical histology lost more IDRFs (median: 1[0-9]) than patients with ganglioneuroblastoma (median: 0[0-4]) (P<0.001). The completeness of resection was related only to the number of preoperative IDRFs (P=0.028). Conclusion IDRF assessment after neoadjuvant chemotherapy is useful for predicting completeness of resection of neurogenic tumors. A larger international study is needed to confirm these results and to explore a possible correlation between preoperative IDRF status and survival. Pediatr Blood Cancer 2015;62:1543-1549. © 2015 Wiley Periodicals, Inc.
Author Schleiermacher, Gudrun
Canale, Sandra
Minard-Colin, Véronique
Elie, Caroline
Michon, Jean
Le Cossec, Chloé
Brisse, Hervé J
Galmiche-Rolland, Louise
Valteau-Couanet, Dominique
Irtan, Sabine
Sarnacki, Sabine
Author_xml – sequence: 1
  givenname: Sabine
  surname: Irtan
  fullname: Irtan, Sabine
  email: Correspondence to: Sabine Irtan, Service de Chirurgie Pédiatrique Viscérale - Sorbonnes Universités, UPMC Univ Paris 06, Hôpital Trousseau, Assistance Publique Hôpitaux de Paris, 26, avenue Dr Arnold Netter, 75012 PARIS, France. , sabine.irtan@gmail.com
  organization: Pediatric surgery department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France
– sequence: 2
  givenname: Hervé J
  surname: Brisse
  fullname: Brisse, Hervé J
  organization: Radiology department, Curie institute, Paris, France
– sequence: 3
  givenname: Véronique
  surname: Minard-Colin
  fullname: Minard-Colin, Véronique
  organization: Pediatric Oncology department, Gustave- Roussy Institute, Paris, France
– sequence: 4
  givenname: Gudrun
  surname: Schleiermacher
  fullname: Schleiermacher, Gudrun
  organization: Pediatric Oncology department, Curie institute, Paris, France
– sequence: 5
  givenname: Louise
  surname: Galmiche-Rolland
  fullname: Galmiche-Rolland, Louise
  organization: Pathology department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France
– sequence: 6
  givenname: Chloé
  surname: Le Cossec
  fullname: Le Cossec, Chloé
  organization: Biostatistics department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France
– sequence: 7
  givenname: Caroline
  surname: Elie
  fullname: Elie, Caroline
  organization: Biostatistics department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France
– sequence: 8
  givenname: Sandra
  surname: Canale
  fullname: Canale, Sandra
  organization: Radiology department, Gustave-Roussy Institute, Paris, France
– sequence: 9
  givenname: Jean
  surname: Michon
  fullname: Michon, Jean
  organization: Pediatric Oncology department, Curie institute, Paris, France
– sequence: 10
  givenname: Dominique
  surname: Valteau-Couanet
  fullname: Valteau-Couanet, Dominique
  organization: Pediatric Oncology department, Gustave- Roussy Institute, Paris, France
– sequence: 11
  givenname: Sabine
  surname: Sarnacki
  fullname: Sarnacki, Sabine
  organization: Pediatric surgery department, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25820608$$D View this record in MEDLINE/PubMed
BookMark eNp1kctu1DAUhi1URC-w4AWQJTawSGs7cZwsIYJSqYKKi1haHud46mlip7ZTmLfiEfEwMxWqYGXr6Pv_c_mP0YHzDhB6TskpJYSdTQt9yjin9BE6orziBSdUHNz_SXuIjmNcZbQmvHmCDhlvGKlJc4R-XYxqCUUPxjrocbDxBhulkw9YxQgxjuAS9gY7mINfgrMap3n0IWJlEoRc96pfzXcqY_oaRp-uIahpjW3EcwQzD9hksylAb3WybomtS0EVfspYsnfwd89s6nqcHbD24zRAApdH2LQPECHLvXuKHhs1RHi2e0_Qt_fvvnYfistP5xfdm8tCVy2hBVe1UcwQCpS3LWMlp0z0JRV1LVjFWAOlolrrssn30ZVQ-TZC5SpXbW0WtDxBr7a-U_C3M8QkRxs1DIPKG89RUkFaKmhL2oy-fICu_Bxcnk7Sum0qQhq-MXyxo-bFCL2cgh1VWMt9Fhk42wI6-BgDGKltUpud873sICmRm7RlTlv-STsrXj9Q7E3_xe7cf9gB1v8H5dXbbq8otgobE_y8V6hwI2tRCi6_fzyXXz5T0XX0SvLyNy0_ymk
CitedBy_id crossref_primary_10_1007_s00383_018_4241_5
crossref_primary_10_1016_j_jpedsurg_2024_162108
crossref_primary_10_1200_JCO_19_03117
crossref_primary_10_3892_ol_2022_13329
crossref_primary_10_1186_s12893_024_02508_x
crossref_primary_10_1007_s00383_023_05477_z
crossref_primary_10_1002_pbc_27670
crossref_primary_10_1007_s00431_023_04899_0
crossref_primary_10_1186_s12880_020_00503_1
crossref_primary_10_1186_s43055_020_00205_2
crossref_primary_10_4103_ijpm_ijpm_362_21
crossref_primary_10_1097_MPH_0000000000001607
crossref_primary_10_1186_s12887_017_0826_8
crossref_primary_10_1002_pbc_27955
crossref_primary_10_1002_pbc_26605
crossref_primary_10_1097_MOP_0000000000000439
crossref_primary_10_1002_pbc_31317
crossref_primary_10_12998_wjcc_v7_i12_1499
crossref_primary_10_1016_j_ijrobp_2018_11_041
crossref_primary_10_1016_j_jpedsurg_2021_04_030
crossref_primary_10_2214_AJR_20_25310
crossref_primary_10_1136_wjps_2022_000531
crossref_primary_10_1245_s10434_021_10381_8
crossref_primary_10_1007_s12519_019_00274_y
crossref_primary_10_23736_S1824_4785_18_03031_5
crossref_primary_10_1002_pbc_31161
crossref_primary_10_1053_j_sempedsurg_2019_04_014
crossref_primary_10_1111_ans_19420
crossref_primary_10_1002_pbc_27867
crossref_primary_10_1007_s00383_020_04627_x
crossref_primary_10_1186_s40644_020_00366_3
crossref_primary_10_1007_s00261_022_03596_0
crossref_primary_10_3389_fped_2021_761896
crossref_primary_10_3390_jcm12237297
crossref_primary_10_1007_s00383_020_04731_y
crossref_primary_10_1136_wjps_2020_000129
crossref_primary_10_1016_j_jpedsurg_2019_02_040
crossref_primary_10_1007_s00247_020_04960_2
crossref_primary_10_1007_s00383_020_04696_y
crossref_primary_10_3390_children10010089
crossref_primary_10_1097_MD_0000000000016752
crossref_primary_10_3390_uro1040028
crossref_primary_10_1016_j_sipas_2023_100195
crossref_primary_10_1007_s00247_016_3572_4
crossref_primary_10_1097_SLA_0000000000003947
crossref_primary_10_1007_s00383_022_05361_2
crossref_primary_10_1590_0102_6720201700020003
crossref_primary_10_2147_OTT_S324015
crossref_primary_10_1111_1759_7714_13277
crossref_primary_10_4103_ajps_ajps_152_21
crossref_primary_10_1016_j_jpedsurg_2016_02_069
crossref_primary_10_21682_2311_1267_2019_6_3_31_43
crossref_primary_10_1002_pbc_31218
crossref_primary_10_1007_s00383_016_3932_z
crossref_primary_10_1089_lap_2016_0390
crossref_primary_10_1002_pbc_30724
crossref_primary_10_1016_j_clon_2021_10_014
crossref_primary_10_1002_cam4_3663
crossref_primary_10_1245_s10434_021_10386_3
crossref_primary_10_1002_pbc_29260
crossref_primary_10_1002_pbc_25585
Cites_doi 10.1016/j.ejca.2008.09.016
10.1200/JCO.2000.18.3.477
10.1016/j.jpedsurg.2010.09.075
10.1016/j.molonc.2008.07.002
10.1148/radiol.11101352
10.1016/S0959-8049(97)00308-0
10.1200/JCO.2011.35.9570
10.1002/pbc.21343
10.1200/JCO.2008.17.5877
10.1016/0022-3468(95)90576-6
10.1200/JCO.1993.11.8.1466
10.1055/s-0031-1280824
10.1200/JCO.2005.02.4661
10.1016/j.jpedsurg.2003.11.028
10.1200/JCO.2012.45.9339
10.1007/s00383-012-3109-3
10.1200/JCO.2000.18.1.18
10.1055/s-2002-36952
10.1200/JCO.1988.6.12.1874
10.1200/JCO.2008.16.6876
10.1016/S0022-3468(96)90486-8
ContentType Journal Article
Copyright 2015 Wiley Periodicals, Inc.
Copyright_xml – notice: 2015 Wiley Periodicals, Inc.
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7TO
8FD
FR3
H94
K9.
P64
RC3
DOI 10.1002/pbc.25511
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Neurosciences Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
DatabaseTitleList
MEDLINE
Neurosciences Abstracts
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1545-5017
EndPage 1549
ExternalDocumentID 3754264441
25820608
10_1002_pbc_25511
PBC25511
ark_67375_WNG_SR17CC1P_5
Genre article
Journal Article
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1L6
1OB
1OC
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RX1
RYL
SUPJJ
SV3
TEORI
UB1
UDS
V2E
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
XV2
~IA
~WT
AAHHS
AAYXX
ACCFJ
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TK
7TO
8FD
FR3
H94
K9.
P64
RC3
ID FETCH-LOGICAL-c4901-5a6fa2f01e15992235127d31766724228e3a1ccc38500c47a0267a8e35a96fb13
IEDL.DBID DR2
ISSN 1545-5009
IngestDate Sun Aug 24 04:01:52 EDT 2025
Fri Jul 25 07:29:45 EDT 2025
Thu Apr 03 07:04:50 EDT 2025
Thu Apr 24 22:57:27 EDT 2025
Tue Jul 01 03:53:06 EDT 2025
Wed Aug 20 07:24:36 EDT 2025
Sun Sep 21 06:21:39 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords neuroblastoma
surgical complications
IDRF
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2015 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4901-5a6fa2f01e15992235127d31766724228e3a1ccc38500c47a0267a8e35a96fb13
Notes ark:/67375/WNG-SR17CC1P-5
istex:C63008FF01659A5D14096373D61D994F47AD07C7
ArticleID:PBC25511
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 25820608
PQID 1698400851
PQPubID 1036357
PageCount 7
ParticipantIDs proquest_miscellaneous_1709171909
proquest_journals_1698400851
pubmed_primary_25820608
crossref_citationtrail_10_1002_pbc_25511
crossref_primary_10_1002_pbc_25511
wiley_primary_10_1002_pbc_25511_PBC25511
istex_primary_ark_67375_WNG_SR17CC1P_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2015
PublicationDateYYYYMMDD 2015-09-01
PublicationDate_xml – month: 09
  year: 2015
  text: September 2015
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Glenview
PublicationTitle Pediatric blood & cancer
PublicationTitleAlternate Pediatr Blood Cancer
PublicationYear 2015
Publisher Blackwell Publishing Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley Subscription Services, Inc
References Haase GM, Atkinson JB, Stram DO, Lukens JN, Matthay KK. Surgical management and outcome of locoregional neuroblastoma: Comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 1995; 30:289-294.
Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer 2008; 50:965-969.
Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A children's cancer group study. J Clin Oncol 2000; 18:18-26.
Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier- Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau- Couanet D. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S. Mol Oncol 2008; 2:261-271.
Rich BS, McEvoy MP, Kelly NE, Oh E, Abramson SJ, Price AP, Cheung NK, La Quaglia MP. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg 2011; 46:103-107.
La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, Rosen N, Wolden S, Cheung NK. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004; 39:412-417.
Castleberry RP. Neuroblastoma. Eur J Cancer 1997; 33:1430-1437.
Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009; 27:298-303.
Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6:1874-1881.
Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 2000; 18:477-486.
Simon T, Häberle B, Hero B, von Schweinitz D, Berthold F. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol 2013; 31:752-758.
Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol 2011; 29:4358-4364.
Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Tomà P, Rizzo A, Michon J, Holmes K. Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23:8483-8489.
Günther P, Holland-Cunz S, Schupp CJ, Stockklausner C, Hinz U, Schenk JP. Significance of image-defined risk factors for surgical complications in patients with abdominal neuroblastoma. Eur J Pediatr Surg 2011; 21:314-317.
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-1477.
Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T. Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261:243-257.
Zwaveling S, Tytgat GA, van der Zee DC, Wijnen MH, Heij HA. Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95% tumour resection suffice. Pediatr Surg Int 2012; 28:953-959.
De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 27:1034-1040.
Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK. Management and outcome of stage 3 neuroblastoma. Eur J Cancer 2009; 45:90-98.
Von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 2002; 12:402-409.
Powis MR, Imeson JD, Holmes SJ. The effect of complete excision on stage III neuroblastoma: A report of the European Neuroblastoma Study Group. J Pediatr Surg 1996; 31:516-519.
2009; 45
1995; 30
2000; 18
1997; 33
2004; 39
1993; 11
1988; 6
2002; 12
2013; 31
2011; 21
2011; 46
2012; 28
2008; 50
2011; 261
2008; 2
2011; 29
2009; 27
2005; 23
1996; 31
e_1_2_6_21_1
e_1_2_6_10_1
e_1_2_6_20_1
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_19_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_13_1
e_1_2_6_14_1
e_1_2_6_3_1
e_1_2_6_11_1
e_1_2_6_2_1
e_1_2_6_12_1
e_1_2_6_22_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_15_1
e_1_2_6_16_1
References_xml – reference: Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Tomà P, Rizzo A, Michon J, Holmes K. Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23:8483-8489.
– reference: Simon T, Häberle B, Hero B, von Schweinitz D, Berthold F. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol 2013; 31:752-758.
– reference: Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T. Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261:243-257.
– reference: De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 27:1034-1040.
– reference: Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier- Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau- Couanet D. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S. Mol Oncol 2008; 2:261-271.
– reference: Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 2000; 18:477-486.
– reference: Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009; 27:298-303.
– reference: Von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 2002; 12:402-409.
– reference: Castleberry RP. Neuroblastoma. Eur J Cancer 1997; 33:1430-1437.
– reference: Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-1477.
– reference: La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, Rosen N, Wolden S, Cheung NK. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004; 39:412-417.
– reference: Powis MR, Imeson JD, Holmes SJ. The effect of complete excision on stage III neuroblastoma: A report of the European Neuroblastoma Study Group. J Pediatr Surg 1996; 31:516-519.
– reference: Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988; 6:1874-1881.
– reference: Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK. Management and outcome of stage 3 neuroblastoma. Eur J Cancer 2009; 45:90-98.
– reference: Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol 2011; 29:4358-4364.
– reference: Haase GM, Atkinson JB, Stram DO, Lukens JN, Matthay KK. Surgical management and outcome of locoregional neuroblastoma: Comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 1995; 30:289-294.
– reference: Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A children's cancer group study. J Clin Oncol 2000; 18:18-26.
– reference: Rich BS, McEvoy MP, Kelly NE, Oh E, Abramson SJ, Price AP, Cheung NK, La Quaglia MP. Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries. J Pediatr Surg 2011; 46:103-107.
– reference: Zwaveling S, Tytgat GA, van der Zee DC, Wijnen MH, Heij HA. Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95% tumour resection suffice. Pediatr Surg Int 2012; 28:953-959.
– reference: Günther P, Holland-Cunz S, Schupp CJ, Stockklausner C, Hinz U, Schenk JP. Significance of image-defined risk factors for surgical complications in patients with abdominal neuroblastoma. Eur J Pediatr Surg 2011; 21:314-317.
– reference: Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer 2008; 50:965-969.
– volume: 31
  start-page: 516
  year: 1996
  end-page: 519
  article-title: The effect of complete excision on stage III neuroblastoma: A report of the European Neuroblastoma Study Group
  publication-title: J Pediatr Surg
– volume: 27
  start-page: 1034
  year: 2009
  end-page: 1040
  article-title: Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without gene amplification
  publication-title: J Clin Oncol
– volume: 30
  start-page: 289
  year: 1995
  end-page: 294
  article-title: Surgical management and outcome of locoregional neuroblastoma: Comparison of the Childrens Cancer Group and the international staging systems
  publication-title: J Pediatr Surg
– volume: 11
  start-page: 1466
  year: 1993
  end-page: 1477
  article-title: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
  publication-title: J Clin Oncol
– volume: 21
  start-page: 314
  year: 2011
  end-page: 317
  article-title: Significance of image‐defined risk factors for surgical complications in patients with abdominal neuroblastoma
  publication-title: Eur J Pediatr Surg
– volume: 27
  start-page: 298
  year: 2009
  end-page: 303
  article-title: The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report
  publication-title: J Clin Oncol
– volume: 23
  start-page: 8483
  year: 2005
  end-page: 8489
  article-title: Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group
  publication-title: J Clin Oncol
– volume: 31
  start-page: 752
  year: 2013
  end-page: 758
  article-title: Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis
  publication-title: J Clin Oncol
– volume: 33
  start-page: 1430
  year: 1997
  end-page: 1437
  article-title: Neuroblastoma
  publication-title: Eur J Cancer
– volume: 18
  start-page: 18
  year: 2000
  end-page: 26
  article-title: Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A children's cancer group study
  publication-title: J Clin Oncol
– volume: 18
  start-page: 477
  year: 2000
  end-page: 486
  article-title: Favorable biology and outcome of stage IV‐S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study
  publication-title: J Clin Oncol
– volume: 6
  start-page: 1874
  year: 1988
  end-page: 1881
  article-title: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
  publication-title: J Clin Oncol
– volume: 28
  start-page: 953
  year: 2012
  end-page: 959
  article-title: Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95% tumour resection suffice
  publication-title: Pediatr Surg Int
– volume: 261
  start-page: 243
  year: 2011
  end-page: 257
  article-title: Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project
  publication-title: Radiology
– volume: 45
  start-page: 90
  year: 2009
  end-page: 98
  article-title: Management and outcome of stage 3 neuroblastoma
  publication-title: Eur J Cancer
– volume: 29
  start-page: 4358
  year: 2011
  end-page: 4364
  article-title: Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age
  publication-title: J Clin Oncol
– volume: 46
  start-page: 103
  year: 2011
  end-page: 107
  article-title: Resectability and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral arteries
  publication-title: J Pediatr Surg
– volume: 50
  start-page: 965
  year: 2008
  end-page: 969
  article-title: Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial
  publication-title: Pediatr Blood Cancer
– volume: 2
  start-page: 261
  year: 2008
  end-page: 271
  article-title: ‐non‐amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S
  publication-title: Mol Oncol
– volume: 12
  start-page: 402
  year: 2002
  end-page: 409
  article-title: The impact of surgical radicality on outcome in childhood neuroblastoma
  publication-title: Eur J Pediatr Surg
– volume: 39
  start-page: 412
  year: 2004
  end-page: 417
  article-title: The impact of gross total resection on local control and survival in high‐risk neuroblastoma
  publication-title: J Pediatr Surg
– ident: e_1_2_6_13_1
  doi: 10.1016/j.ejca.2008.09.016
– ident: e_1_2_6_21_1
  doi: 10.1200/JCO.2000.18.3.477
– ident: e_1_2_6_14_1
  doi: 10.1016/j.jpedsurg.2010.09.075
– ident: e_1_2_6_20_1
  doi: 10.1016/j.molonc.2008.07.002
– ident: e_1_2_6_6_1
  doi: 10.1148/radiol.11101352
– ident: e_1_2_6_2_1
  doi: 10.1016/S0959-8049(97)00308-0
– ident: e_1_2_6_22_1
  doi: 10.1200/JCO.2011.35.9570
– ident: e_1_2_6_18_1
  doi: 10.1002/pbc.21343
– ident: e_1_2_6_7_1
  doi: 10.1200/JCO.2008.17.5877
– ident: e_1_2_6_12_1
  doi: 10.1016/0022-3468(95)90576-6
– ident: e_1_2_6_3_1
  doi: 10.1200/JCO.1993.11.8.1466
– ident: e_1_2_6_19_1
  doi: 10.1055/s-0031-1280824
– ident: e_1_2_6_9_1
  doi: 10.1200/JCO.2005.02.4661
– ident: e_1_2_6_16_1
  doi: 10.1016/j.jpedsurg.2003.11.028
– ident: e_1_2_6_15_1
  doi: 10.1200/JCO.2012.45.9339
– ident: e_1_2_6_17_1
  doi: 10.1007/s00383-012-3109-3
– ident: e_1_2_6_8_1
  doi: 10.1200/JCO.2000.18.1.18
– ident: e_1_2_6_10_1
  doi: 10.1055/s-2002-36952
– ident: e_1_2_6_4_1
  doi: 10.1200/JCO.1988.6.12.1874
– ident: e_1_2_6_5_1
  doi: 10.1200/JCO.2008.16.6876
– ident: e_1_2_6_11_1
  doi: 10.1016/S0022-3468(96)90486-8
SSID ssj0026058
Score 2.364903
Snippet Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image‐defined risk factors (IDRFs). We examined...
Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined the added...
Background Patients with neuroblastoma are now stratified at diagnosis according to the presence and number of image-defined risk factors (IDRFs). We examined...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1543
SubjectTerms Abdominal Neoplasms - diagnostic imaging
Abdominal Neoplasms - drug therapy
Abdominal Neoplasms - epidemiology
Abdominal Neoplasms - pathology
Abdominal Neoplasms - surgery
Adolescent
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Child
Child, Preschool
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Diagnostic Imaging - methods
Etoposide - administration & dosage
Female
Ganglioneuroblastoma - diagnostic imaging
Ganglioneuroblastoma - drug therapy
Ganglioneuroblastoma - epidemiology
Ganglioneuroblastoma - pathology
Ganglioneuroblastoma - surgery
Hematology
Hematopoietic Stem Cell Transplantation
Humans
IDRF
Infant
Kaplan-Meier Estimate
Magnetic Resonance Imaging
Male
Neoadjuvant Therapy
Neoplasm Staging
Neoplasm, Residual
neuroblastoma
Neuroblastoma - diagnostic imaging
Neuroblastoma - drug therapy
Neuroblastoma - epidemiology
Neuroblastoma - pathology
Neuroblastoma - surgery
Oncology
Pediatrics
Postoperative Complications - epidemiology
Postoperative Complications - prevention & control
Risk Assessment
Risk Factors
surgical complications
Thoracic Neoplasms - diagnostic imaging
Thoracic Neoplasms - drug therapy
Thoracic Neoplasms - epidemiology
Thoracic Neoplasms - pathology
Thoracic Neoplasms - surgery
Tomography, X-Ray Computed
Treatment Outcome
Vincristine - administration & dosage
Title Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection
URI https://api.istex.fr/ark:/67375/WNG-SR17CC1P-5/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpbc.25511
https://www.ncbi.nlm.nih.gov/pubmed/25820608
https://www.proquest.com/docview/1698400851
https://www.proquest.com/docview/1709171909
Volume 62
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3NbtQwEMetqpUQFyjfoQUZhBCXbDcfthtxgoVSkKiqQkUPSJbjD2lpd7PaJFLhxCP0YfpEPAkzdhIoKhLitvLOxs7O2PklmfmbkCdjazKWCxvbAu5N8txlsbLcxSw3WclhOeTKZ1vs8d3D_N0RO1ohz_tamKAPMTxww5nh12uc4Kqst36Jhi5KPQIe9nW9ScZRN__VwSAdhZjuy-CAEGIGINGrCo3TreGXF65Fa_i3nl4Gmhe51V94dq6Tz_2QQ77J8ahtypH-9oea43-e0zq51gEpfREi6AZZsfOb5Mr77pX7LXL-dgZLzo_vZ8Y6aDAUk9Fp2KaHqkHXk1aOem1MCMippk07q5Y19TuQQ3ulzJcWmL2hECOzrujrK53WtK2ta08ooDNdLLFTTMOmU3zkDH1WCxuUyX_vFQ47NxSOQX0-PFI_DAIHgKVUvk7jNjncef1xsht3Wz3EOgciiZniTqVunFjAqwKQBThEmAzVK0WKKmU2U4nWOtsGX-pcKNw4S0ErUwV3ZZLdIavzam7vEcocKzlQj7Xc5gVXyhkjnLHKCsTd7Yg8650udaeDjttxnMig4JxK8IL0XojI48F0EcQ_LjN66iNnsFDLY8yWE0x-2nsjPxwkYjJJ9iWLyGYfWrJbKGqZ8AJusZF7I_Jo-BqmOL63UeCfFmwEQJ0AcisicjeE5NBZylCAf4xn5QPr7-OU-y8n_sP9fzfdIFcBEFnIqdskq82ytQ8AwpryoZ9tPwE5CjE-
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3bbtQwEIZHVSsBN5wPKQUMQoibbDcH243EDawoW2hXVWlFbyrLiW1pafeg3UQCrngEHoYn4kmYcQ5QVCTE3crrjSfrsfPFnvkN8LRvTcJTaUOb4btJmrok1Fa4kKcmyQVOh0L7aIuRGB6lb4_58Qq8aHNhan2IbsGNRoafr2mA04L05i_V0Hle9BCIKbF3ze_PERIddOJRBOo-EQ4ZIeSIEq2uUD_e7H567mm0Rn_sp4tQ8zy5-kfP9jU4aY2uI05Oe1WZ94ovf-g5_u9dXYerDZOyl7UT3YAVO70Jl_aaXfdb8H1ngrPOj6_fjHVYYBjFo7P6pB6mO2lPNnPMy2OiT44LVlaT2WLJ_CHkWD7T5mOF2F4ydJNJk_f1mY2XrFpatI4hPbP5ghqlSGw2plVnbHM2t7U4-e-t4mWnhuE1mA-JJ_BHI8gAyqbyqRq34Wj79eFgGDanPYRFilASci2cjl0_skhYGVILoog0CQlYypiEymyio6Ioki3szCKVms7O0ljKdSZcHiV3YHU6m9p7wLjjuUDwsVbYNBNaO2OkM1ZbScS7FcDzttdV0Uih04kcZ6oWcY4V9oLyvRDAk67qvNb_uKjSM-86XQ29OKWAOcnVh9Eb9f4gkoNBtK94AButb6lmrliqSGT4lk3oG8Dj7msc5bR1o7F_KqwjkeskwlsWwN3aJ7vGYk4a_H26K-9Zf7dT7b8a-A_r_171EVweHu7tqt2d0bv7cAV5kdchdhuwWi4q-wCZrMwf-qH3EyYxNVw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1bb9MwFMetaZMmXrhfsg0wCCFe0jWJL4t4gkLZuFTVYGIPSJYT21LZ2kRtIgFPfAQ-DJ-IT8I5zgWGhoR4i5zT2KmP7V-Sc_4m5MHQmoQzaUObwrMJYy4JtRUu5MwkmYDpUGgfbTER-0fs5TE_XiOPu1yYRh-if-GGI8PP1zjAS-N2f4mGllk-AB7GvN4NJmCZRCI67LWjkNN9HhwgQsiBJDpZoWG82__0zGK0gf_rp_NI8yy4-pVnfIl86NrcBJycDOoqG-Rf_pBz_M-bukwutkRKnzQudIWs2cVVsvmm_eZ-jXw_mMOc8-PrN2MdFBiK0ei02aeH6l7YkxaOenFM8MhZTqt6XixX1G9BDuWFNh9rgPaKgpPM26yvz3S2ovXKuvqUAjvTcomVYhw2neE7Z6izKG0jTf57rXDZhaFwDeoD4hH7oRHYAMyl8oka18nR-Pm70X7Y7vUQ5gyQJORaOB27YWSBr1JgFgARaRKUr5QxypTZREd5nid70Jc5kxp3ztJQynUqXBYlN8j6oljYW4RyxzMB2GOtsCwVWjtjpDNWW4m8uxeQR12nq7wVQsf9OE5VI-EcK-gF5XshIPd707JR_zjP6KH3nN5CL08wXE5y9X7yQr09jORoFE0VD8hO51qqnSlWKhIpPGMj-AbkXn8axjh-uNHQPzXYSKA6CeiWBuRm45J9ZTFHBf4h3pV3rL-3U02fjvzB1r-b3iWb02dj9fpg8mqbXABY5E183Q5Zr5a1vQ1AVmV3_MD7CWsiNAs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Image-defined+risk+factor+assessment+of+neurogenic+tumors+after+neoadjuvant+chemotherapy+is+useful+for+predicting+intra-operative+risk+factors+and+the+completeness+of+resection&rft.jtitle=Pediatric+blood+%26+cancer&rft.au=Irtan%2C+Sabine&rft.au=Brisse%2C+Herv%C3%A9+J&rft.au=Minard-Colin%2C+V%C3%A9ronique&rft.au=Schleiermacher%2C+Gudrun&rft.date=2015-09-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1545-5009&rft.eissn=1545-5017&rft.volume=62&rft.issue=9&rft.spage=1543&rft.epage=1549&rft_id=info:doi/10.1002%2Fpbc.25511&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_SR17CC1P_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1545-5009&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1545-5009&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1545-5009&client=summon